Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2Unknown 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 34Thoracic 30Dermatologic 16Genitourinary 14Head & Neck 12Gynecologic 10Breast 9Lymphoid 5Other solid neoplasm 2CNS 2

Conditions

Brain Neoplasms 1050Glioblastoma 920Glioma 601Central Nervous System Neoplasms 436Astrocytoma 396Gliosarcoma 339Neuroblastoma 325Oligodendroglioma 255Neoplasms 181Medulloblastoma 165Breast Neoplasms 154Sarcoma 114Recurrence 108Ependymoma 105Neoplasm Metastasis 95Meningioma 91Melanoma 88Lymphoma 87Carcinoma, Non-Small-Cell Lung 87Lung Neoplasms 82Precursor Cell Lymphoblastic Leukemia-Lymphoma 79Neurofibromatosis 1 78Wilms Tumor 75Osteosarcoma 69Head and Neck Neoplasms 69Ovarian Neoplasms 68Testicular Neoplasms 67Lymphoma, Non-Hodgkin 67Burkitt Lymphoma 66Familial ependymoma 63

Interventions

pembrolizumab 1lenvatinib 1avelumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Parkinson Disease 4, Autosomal Dominant Lewy Body × CNS × Clear all
NCT03797326 2026-05-04

LEAP-005

Merck Sharp & Dohme LLC

Phase 2 Completed
611 enrolled 27 charts
BreastCNSGastrointestinalGynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Biliary Tract Neoplasms, Glioblastoma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT02968940 2022-06-29

Avelumab With Hypofractionated Radiation Therapy in Adults With Isocitrate Dehydrogenase (IDH) Mutant Glioblastoma

NYU Langone Health

Phase 2 Completed
6 enrolled 10 charts
CNS

Parkinson Disease 4, Autosomal Dominant Lewy Body, Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡